Below is a summary of the ground-breaking MIA research projects discussed at ESMO23:
ESMO Women for Oncology Award lecture: Breaking ground in 2023. Prof Georgina Long AO.
Controversy session: All patients with resected stage IIB/IIC should be treated with adjuvant anti-PD1 therapy
Session Chair Georgina V Long
Special Symposium: What’s the future in melanoma therapy? Novel targets, new drugs, reinvented approaches
Ines Pires da Silva – Clinical data, NGS, (x)-omics et al.: What is the ideal mixture to identify and overcome primary resistance to immune-checkpoint inhibitors?
Multidisciplinary session – Early-stage (II/III) melanoma: Risk stratification and treatment decisions
Alexander Van Akkooi – Further development of the clinical case: A surgeon’s perspective – Do we still need surgery in the era of risk scores stratification and systemic therapy?
Mini Oral session – Melanoma and other skin tumours – Chair Georgina V Long
Invited Discussant 1083MO and 1084MO – Georgina V Long
Posters – MIA presenting:
1103P – Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Speaker: Georgina V Long
1106P – Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets).
Speaker: Ines Pires da Silva
1149P – Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment.
Speaker: Lisanne Zijlker
1165P – Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy
Speaker: Xinyu Bai
Posters – MIA Author, Other Institution presenting
1089P – Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Speaker: Paolo A Ascierto
1091P – Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma
Speaker: Jeffrey S Weber
1095P – Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Speaker: Irene Reijers
1096P – Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma
Speaker Minke W Lucas
1099P – Long-term survival follow-up from the REDUCTOR trial: Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection
Speaker Femke H Burgers
1120P – Development and external validation of a clinical prediction model to predict recurrence-free survival and melanoma-specific survival in patients with melanoma after sentinel lymph node biopsy
Speaker Robert C Stassen
1127P – Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis
Speaker: James P Pham